Glutathione S-conjugation of the sevoflurane degradation product, fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (compound A) in human liver, kidney, and blood in vitro

被引:8
作者
Altuntas, TG
Kharasch, ED
机构
[1] Univ Washington, Dept Anesthesiol, Seattle, WA 98195 USA
[2] Univ Washington, Dept Med Chem, Seattle, WA 98195 USA
关键词
D O I
10.1006/taap.2001.9302
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether (FDVE) is a fluorinated alkene formed by degradation of the volatile anesthetic sevoflurane in anesthesia machines. FDVE is nephrotoxic in rats and undergoes glutathione-dependent conjugation to form two alkane (G1, G2) and two alkene glutathione S-conjugates (G3, G4), cleavage to cysteine S-conjugates, and beta -lyase-catalyzed metabolism to reactive thionoacyl fluorides, which may react with cellular macromolecules to cause nephrotoxicity. Although similar metabolites have been identified in human urine in vivo, little is known about sites and mechanisms of GSH conjugation in humans. This investigation quantified FDVE-GSH conjugates formed by human hepatic and renal microsomal and cytosolic fractions and blood in vitro. LC-MS/MS analysis identified all four GSH conjugates (G1-G4) formed in all human subcellular fractions. Quantitative analysis indicated that the relative order of formation was G2 > G1 > G4 > G3 with human liver and kidney subfractions. In blood, the order was G1 > G4 > G2 > G3. These results demonstrate that FDVE undergoes GSH-dependent conjugation in human liver and kidney microsomes and cytosol as well as blood, which may account for the detection of corresponding mercapturic acids in the urine of patients exposed to FDVE. (C) 2001 Elsevier Science.
引用
收藏
页码:85 / 93
页数:9
相关论文
共 37 条
[31]  
LOWRY OH, 1951, J BIOL CHEM, V193, P265
[32]   REACTION OF SEVOFLURANE AND ITS DEGRADATION PRODUCTS WITH SODA LIME - TOXICITY OF THE BY-PRODUCTS [J].
MORIO, M ;
FUJII, K ;
SATOH, N ;
IMAI, M ;
KAWAKAMI, U ;
MIZUNO, T ;
KAWAI, Y ;
OGASAWARA, Y ;
TAMURA, T ;
NEGISHI, A ;
KUMAGAI, Y ;
KAWAI, T .
ANESTHESIOLOGY, 1992, 77 (06) :1155-1164
[33]   The effects of prolonged low-flow sevoflurane anesthesia on renal and hepatic function [J].
Obata, R ;
Bito, H ;
Ohmura, M ;
Moriwaki, G ;
Ikeuchi, Y ;
Katoh, T ;
Sato, S .
ANESTHESIA AND ANALGESIA, 2000, 91 (05) :1262-1268
[34]   Dose-dependent protein adduct formation in kidney, liver, and blood of rats and in human blood after perchloroethene inhalation [J].
Pähler, A ;
Parker, J ;
Dekant, W .
TOXICOLOGICAL SCIENCES, 1999, 48 (01) :5-13
[35]  
PARONI R, 1995, CLIN CHEM, V41, P448
[36]   Evidence for metabolism of fluoromethyl 2,2-difluoro-1-(trifluoromethyl)vinyl ether (Compound A), a sevoflurane degradation product, by cysteine conjugate beta-lyase [J].
Spracklin, DK ;
Kharasch, ED .
CHEMICAL RESEARCH IN TOXICOLOGY, 1996, 9 (04) :696-702
[37]   Biotransformation of perchloroethene:: Dose-dependent excretion of trichloroacetic acid, dichloroacetic acid, and N-acetyl-S-(trichlorovinyl)-L-cysteine in rats and humans after inhalation [J].
Völkel, W ;
Friedewald, M ;
Lederer, E ;
Pähler, A ;
Parker, J ;
Dekant, W .
TOXICOLOGY AND APPLIED PHARMACOLOGY, 1998, 153 (01) :20-27